This is an A-1 revision of a competing continuation application for DK55023 which has been active for the past 10 years, and which has served as the basis for the PI's exploration of growth factor, signaling and cell cycle control in the pancreatic beta cell. It is now clear that both Type 1 as well as Type 2 diabetes result in part or entirely from beta cell deficiency and/or dysfunction, and that beta cell replacement can reverse diabetes in humans. The two major hurdles to beta cell replacement and regeneration are now an incomplete ability to prevent auto- and allo-immune attack, and a grossly inadequate supply of human beta cells. This renewal application addresses the second hurdle. While it is now abundantly clear that it is possible to activate rodent beta cell replication, human beta cells remain refractory to replication induced by growth factors, nutrients, and signaling pathway activation. Our group has characterized the murine and human beta cell cycle control machinery and has developed cell-cycle based approaches to driving robust human beta cell replication. In this application, we describe studies focused on three interesting and surprising cell cycle regulators that have emerged from prior versions of this grant: p57, cMyc and p107. Most investigators would not intuitively have selected these three as likely candidates for normal cell cycle control and human beta cell expansion. We believe that the data presented herein move them from among the least interesting to among the most interesting and potentially important candidates for regulating beta cell proliferation in rodents and humans. Thus, the Specific Aims of this proposal are:
Specific Aim 1. To Define the Importance of p57 in Restraining Rodent and Human Beta Cell Replication.
Specific Aim 2. To Define the Pathophysiology and Therapeutic Potential of Mild, Graded and Transient cMyc Overexpression in Rat and Human Beta Cells.
Specific Aim 3. To Define the Relevance of the Pocket Protein, p107, in Mouse and Human Beta Cell Cycle Repression. These studies should provide important insight into how beta cell replication is controlled and lead to insight into how one might develop methods to activate these key molecules in the human beta cell, and permit inducible, regulated human beta cell replication.
Type 1 and Type 2 diabetes have reached epidemic proportions worldwide. A major goal of the NIH and NIDDK is to develop mechanisms to induce human beta cell replication and regeneration in a way that permits retained beta cell function. Whereas it is now relatively easy to induce rodent beta cell replication, human beta cells have proven to be refractory to replication. Thus, a need exists for molecules and pathways that can lead ot human beta cell expansion. In this application, we provide what we believe is compelling evidence that three molecules - p57, cMyc and p107 - are of particular importance in controlling beta cell replication, and describe how they might be manipulated to induce robust and therapeutic human beta cell replication. The studies described herein should shed light on how best to induce therapeutic human beta cell replication and regeneration, whether the ultimate source of beta cells is human cadaveric islets, human embryonic stem cells, induced pluripotent stem cells or porcine islets.
|Chen, Hainan; Kleinberger, Jeffrey W; Takane, Karen K et al. (2015) Augmented Stat5 Signaling Bypasses Multiple Impediments to Lactogen-Mediated Proliferation in Human Î²-Cells. Diabetes 64:3784-97|
|Wang, Peng; Fiaschi-Taesch, Nathalie M; Vasavada, Rupangi C et al. (2015) Diabetes mellitus--advances and challenges in human Î²-cell proliferation. Nat Rev Endocrinol 11:201-12|
|Stewart, Andrew F; Hussain, Mehboob A; GarcÃa-OcaÃ±a, Adolfo et al. (2015) Human Î²-cell proliferation and intracellular signaling: part 3. Diabetes 64:1872-85|
|Wang, Peng; Alvarez-Perez, Juan-Carlos; Felsenfeld, Dan P et al. (2015) A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication. Nat Med 21:383-8|
|GarcÃa-OcaÃ±a, Adolfo; Stewart, Andrew F (2014) "RAS"ling Î² cells to proliferate for diabetes: why do we need MEN? J Clin Invest 124:3698-700|
|Stewart, Andrew F (2014) Betatrophin versus bitter-trophin and the elephant in the room: time for a new normal in Î²-cell regeneration research. Diabetes 63:1198-9|
|Bernal-Mizrachi, Ernesto; Kulkarni, Rohit N; Scott, Donald K et al. (2014) Human Î²-cell proliferation and intracellular signaling part 2: still driving in the dark without a road map. Diabetes 63:819-31|
|Bender, Aaron; Stewart, Andrew F (2014) Good news for the ageing beta cell. Diabetologia 57:265-9|
|Fiaschi-Taesch, Nathalie M; Kleinberger, Jeffrey W; Salim, Fatimah G et al. (2013) Cytoplasmic-nuclear trafficking of G1/S cell cycle molecules and adult human Î²-cell replication: a revised model of human Î²-cell G1/S control. Diabetes 62:2460-70|
|Fiaschi-Taesch, Nathalie M; Kleinberger, Jeffrey W; Salim, Fatimah G et al. (2013) Human pancreatic Î²-cell G1/S molecule cell cycle atlas. Diabetes 62:2450-9|
Showing the most recent 10 out of 26 publications